Lichen planus pigmentosus of the face or neck for 6 months or longer that has been confirmed by histopathology. lichen planus pigmentosus, hydroquinone, autologous platelet-rich plasma
Conditions
Interventions
Hydroquinone 4% is topically applied to skin lesions on both sides of the face and/or neck one time per day before bedtime for the entire duration of the study.,Autologous platelet-rich plasma is inje
Placebo Comparator Drug,Experimental Drug
Topical Hydroquinone 4%,Intradermal autologous platelet-rich plasma
Sponsors
Institute of Dermatology, Bangkok, Thailand
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of lichen planus pigmentosus of the face or neck in symmetrical distribution for 6 months or longer that has been confirmed by histopathology 2. Skin patch test negative for standard and extended series
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding 2. Previous allergy to platelet-rich plasma 3. History of bleeding tendency, herpes infection at face or neck, and/or HIV or hepatitis B infection 4. Anti-oxidant supplements (e.g. vitamin C, vitamin E) in the past 3 months 5. Currently on chemotherapy and/or taking anti-coagulant medications 6. Laser treatment at face or neck in the past 3 months 7. Keloids or hypertrophic scars at the face or neck 8. Other skin diseases at injection sites for platelet-rich plasma at face or neck (e.g. infection, inflammation, neoplasm) 9. Participation in a clinical research study in the past 6 months 10. Oral isotretinoin, dapsone, or hydroxychloroquine during the past 3 months 11. Topical corticosteroids, topical calcineurin inhibitors, or topical skin lightening medication in the past 1 month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Melanin Index of three representative skin lesions on both sides of face and/or neck at week 0, 2, 4, 8, 12, 16, and 20 Mexameter,Clinical Assessment by Three Dermatologists at week 0, 2, 4, 8, 12, 16, and 20 Dermal Pigmentation Area and Severity Index (DPASI) for Acquired Dermal Macular Hyperpigmentation (ADMH),Patient's severity of skin lesions at week 2, 4, 8, 12, 16, and 20 Patients rate severity of skin lesions on 0 to 10 scale (0 is least severe, 10 is most severe),Patient's satisfaction of treatment at week 2, 4, 8, 12, 16, and 20 Patients rate satisfaction of treatment on 0 to 3 scale (0 is not satisfied, 2 is satisfied, 3 is very satisfied) | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects assessment at day 1, day 3, day 7 after each treatment and 1, 2, 3, and 4 months after third treatment Side effects record form (e.g. erythema, edema, bleeding, oozing, crusting, post-inflammatory hyperpigmentation) | — |
Countries
Thailand
Contacts
Public ContactPolpatt Jitpakdee
Institute of Dermatology
Outcome results
None listed